1. Adjunctive Brivaracetam in Older Patients with Focal Seizures: Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST)
- Author
-
Simona Lattanzi, 1, Michele Ascoli, 2, Laura Canafoglia, 3, 4 5, Maria Paola Canevini, Sara Casciato, 6, Emanuele Cerulli Irelli, 7, Valentina Chiesa, 4, Filippo Dainese, 8, Giovanni De Maria, 9, Giuseppe Didato 10, Giancarlo Di Gennaro, 6, Giovanni Falcicchio 11, Martina Fanella, 7, Massimo Gangitano 12, Angela La Neve 11, Oriano Mecarelli, 7, Elisa Montalenti 13, Alessandra Morano, 7, Federico Piazza 14, Chiara Pizzanelli 15, Patrizia Pulitano, 7, Federica Ranzato 16, Eleonora Rosati 17, Laura Tassi 18, Carlo Di Bonaventura, 7, BRIVAFIRST Group Collaborators, Affiliations collapse Collaborators BRIVAFIRST Group: Angela Alicino, Giovanni, Assenza, Federica, Avorio, Valeria, Badioni, Paola, Banfi, Emanuele, Bartolini, Luca Manfredi Basili, Vincenzo, Belcastro, Simone, Beretta, Irene, Berto, Martina, Biggi, Giuseppe, Billo, Giovanni, Boero, Paolo, Bonanni, Jole, Bongiorno, Francesco, Brigo, Emanuele, Caggia, Claudia, Cagnetti, Carmen, Calvello, Edward, Cesnik, Gigliola, Chianale, Domenico, Ciampanelli, Roberta, Ciuffini, Dario, Cocito, Donato, Colella, Margerita, Contento, Cinzia, Costa, Eduardo, Cumbo, Alfredo, D'Aniello, Francesco, Deleo, Jacopo, C DiFrancesco, Roberta Di Giacomo, Alessandra Di Liberto, Elisabetta, Domina, Francesco, Donato, Fedele, Dono, Vania, Durante, Maurizio, Elia, Anna, Estraneo, Giacomo, Evangelista, Maria Teresa Faedda, Ylenia, Failli, Elisa, Fallica, Jinane, Fattouch, Alessandra, Ferrari, Ferreri, Florinda, Giacomo, Fisco, Davide, Fonti, Francesco, Fortunato, Nicoletta, Foschi, Teresa, Francavilla, Rosita, Galli, Sara, Gasparini, Stefano, Gazzina, Anna Teresa Giallonardo, Filippo Sean Giorgi, Loretta, Giuliano, Francesco, Habetswallner, Francesca, Izzi, Kassabian, Benedetta, Lorenzo, Kiferle, Angelo, Labate, Concetta, Luisi, Matteo, Magliani, Giulia, Maira, Luisa, Mari, Daniela, Marino, Addolorata, Mascia, Alessandra, Mazzeo, Stefano, Meletti, Chiara, Milano, Annacarmen, Nilo, Biagio, Orlando, Francesco, Paladin, Maria Grazia Pascarella, Chiara, Pastori, Giada, Pauletto, Alessia, Peretti, Gabriella, Perri, Marianna, Pezzella, Marta, Piccioli, Pietro, Pignatta, Nicola, Pilolli, Francesco, Pisani, Laura Rosa Pisani, Fabio, Placidi, Patrizia, Pollicino, Vittoria, Porcella, Monica, Puligheddu, Stefano, Quadri, Pier Paolo Quarato, Rui, Quintas, Rosaria, Renna, Adriana, Rum, Enrico Michele Salamone, Ersilia, Savastano, Maria, Sessa, David, Stokelj, Elena, Tartara, Mario, Tombini, Gemma, Tumminelli, Anna Elisabetta Vaudano, Ilaria, Viganò, Emanuela, Viglietta, Aglaia, Vignoli, Flavio, Villani, Elena, Zambrelli, Lelia, Zummo, Lattanzi S., Canafoglia L., Canevini M.P., Casciato S., Cerulli Irelli E., Chiesa V., Dainese F., De Maria G., Didato G., Falcicchio G., Fanella M., Ferlazzo E., Gangitano M., Giorgi F.S., La Neve A., Mecarelli O., Montalenti E., Morano A., Piazza F., Pulitano P., Quarato P.P., Ranzato F., Rosati E., Tassi L., and Di Bonaventura C.
- Subjects
Antiseizure medication ,Epilepsy ,Settore MED/26 ,Pyrrolidinones ,Focal seizures ,Treatment Outcome ,Drug Therapy ,Double-Blind Method ,Italy ,Seizures ,Brivaracetam ,Combination ,Aged ,Drug Therapy, Combination ,Humans ,Retrospective Studies ,Anticonvulsants ,Pharmacology (medical) ,Settore MED/26 - Neurologia ,Geriatrics and Gerontology - Abstract
BACKGROUND: The management of epilepsy in older adults has become part of daily practice because of an aging population. Older patients with epilepsy represent a distinct and more vulnerable clinical group as compared with younger patients, and they are generally under-represented in randomized placebo-controlled trials. Real-world studies can therefore be a useful complement to characterize the drug's profile. Brivaracetam is a rationally developed compound characterized by high-affinity binding to synaptic vesicle protein 2A and approved as adjunctive therapy for focal seizures in adults with epilepsy. OBJECTIVE: The aim of this study was to assess the 12-month effectiveness and tolerability of adjunctive brivaracetam in older patients (≥65 years of age) with epilepsy treated in a real-world setting. METHODS: The BRIVAFIRST (BRIVAracetam add-on First Italian netwoRk STudy) was a 12-month retrospective multicenter study including adult patients prescribed adjunctive brivaracetam. Effectiveness outcomes included the rates of seizure response (≥50% reduction in baseline seizure frequency), seizure freedom, and treatment discontinuation. Safety and tolerability outcomes included the rate of treatment discontinuation due to adverse events and the incidence of adverse events. Data were compared for patients aged ≥65 years of age ('older') vs those aged
- Published
- 2022